Barrow Hanley Mewhinney & Strauss LLC Lowers Stock Position in Smith & Nephew plc (NYSE:SNN)

Barrow Hanley Mewhinney & Strauss LLC trimmed its holdings in Smith & Nephew plc (NYSE:SNN) by 2.4% during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 4,181,330 shares of the medical equipment provider’s stock after selling 100,740 shares during the quarter. Barrow Hanley Mewhinney & Strauss LLC owned approximately 0.96% of Smith & Nephew worth $103,613,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently bought and sold shares of the business. Optiver Holding B.V. increased its stake in Smith & Nephew by 100.4% in the fourth quarter. Optiver Holding B.V. now owns 599,981 shares of the medical equipment provider’s stock valued at $16,476,000 after purchasing an additional 300,591 shares during the period. Hsbc Holdings PLC increased its position in Smith & Nephew by 80.1% in the 4th quarter. Hsbc Holdings PLC now owns 592,734 shares of the medical equipment provider’s stock valued at $16,152,000 after acquiring an additional 263,641 shares during the period. Dimensional Fund Advisors LP raised its stake in Smith & Nephew by 58.2% during the 2nd quarter. Dimensional Fund Advisors LP now owns 524,602 shares of the medical equipment provider’s stock valued at $12,995,000 after acquiring an additional 193,046 shares during the last quarter. Wells Fargo & Company MN lifted its position in Smith & Nephew by 20.9% during the 4th quarter. Wells Fargo & Company MN now owns 1,003,050 shares of the medical equipment provider’s stock worth $27,363,000 after acquiring an additional 173,448 shares during the period. Finally, Tocqueville Asset Management L.P. lifted its position in Smith & Nephew by 294.9% during the 1st quarter. Tocqueville Asset Management L.P. now owns 224,441 shares of the medical equipment provider’s stock worth $5,692,000 after acquiring an additional 167,599 shares during the period. Hedge funds and other institutional investors own 25.64% of the company’s stock.

Smith & Nephew Price Performance

Shares of SNN stock opened at $30.57 on Friday. The company has a debt-to-equity ratio of 0.63, a current ratio of 2.51 and a quick ratio of 1.11. The stock has a 50 day simple moving average of $30.09 and a 200-day simple moving average of $27.09. Smith & Nephew plc has a 12-month low of $21.52 and a 12-month high of $31.72.

Smith & Nephew Increases Dividend

The firm also recently disclosed a dividend, which will be paid on Friday, November 8th. Investors of record on Friday, October 4th will be issued a dividend of $0.288 per share. The ex-dividend date is Friday, October 4th. This is a positive change from Smith & Nephew’s previous dividend of $0.24.

Analyst Ratings Changes

SNN has been the topic of a number of recent research reports. StockNews.com raised Smith & Nephew from a “buy” rating to a “strong-buy” rating in a report on Monday, August 5th. Deutsche Bank Aktiengesellschaft started coverage on shares of Smith & Nephew in a research note on Wednesday, July 24th. They issued a “buy” rating on the stock. Finally, UBS Group upgraded shares of Smith & Nephew from a “neutral” rating to a “buy” rating in a research note on Wednesday, June 5th. Two equities research analysts have rated the stock with a hold rating, four have given a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy”.

About Smith & Nephew

Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices and services in the United Kingdom and internationally. It operates through three segments: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management. The company offers knee implant products for knee replacement procedures; hip implants for revision procedures; trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures; and other reconstruction products.